PTHL (Pheton Holdings Limited) Market Value to Book Value Ratio

ftzy.com.cn (PTHL) - corporate logo

Pheton Holdings Ltd (PTHL) develops radiotherapy software in China, leveraging experts in analytics and IT development. Production capacities rely on automation, where robots package medications to reduce costs. The price action on GURU.Markets reflects the asset's dynamics, which stand at 3.23. Meanwhile, the business retains key personnel in 3D modeling, completely eliminating the risk of losing intellectual capital.

ftzy.com.cn (PTHL) - Market Value to Book Value from 09/06/2024 to 01/16/2026
Manufactured product of ftzy.com.cn

For the Pheton Holdings Ltd (PTHL) ecosystem, which integrates medtech and clinics, asset value serves as the foundation for valuation. This metric compares the company's current market price with its net equity on the balance sheet. By analyzing the market-to-book ratio on GURU.Markets, an investor determines the extent of the business premium. The price action filters out speculative noise, revealing the actual strength of the trend. This allows for a clear distinction between fundamental undervaluation and a systemic decline in returns.

Competitor analysis

Haleon plc (HLN) - Market Value to Book Value Ratio|KVUE (kenvue.com) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Verona Pharma|Jyong Biotech Limited - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio LGND|AMRX (Amneal Corp) - Market Value to Book Value|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|Market Capitalization to Book Value Ratio alvotech.com ALVO|LQDA - Market Value to Book Value Ratio|Market Value to Book Value GLPG (Galapagos N.V.)|ANI Pharma (ANIP) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Afrezza|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com|Market Cap to Net Assets Ratio SPRY (ARS Pharmaceuticals, Inc.)|TBPH (Theravance Biopharma Inc) - Market Value to Book Value|Market Value to Book Value Ratio Aquestive Pharma AQST|scPharmaceuticals, Inc. (SCPH) - Market-to-Book Ratio|TECX: Market Cap to Net Assets Ratio|tonixpharma.com - Market Cap to Book Value Multiple|SXTC: Market Capitalization to Book Value Ratio|Eupraxia Pharmaceuticals Inc. - Market Value to Book Value|BHST (BioHarvest) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Invizyne EXOZ|Market Value to Book Value Ratio Oramed Pharmaceuticals (ORMP)|ENTX (enterabio.com) - Market Value to Book Value|Market Value to Book Value Ratio MindWalk Holdings Inc. HYFT|ABVC (ABVC BioPharma Inc.) - Market Capitalization to Net Assets|Cumberland Pharma - Market Capitalization to Book Value Ratio|Market Value to Book Value QNTM (Quantum BioPharma Corp)|FGEN: Market Capitalization to Book Value Ratio|Market-to-Book Ratio telomirpharma.com (TELO)|Market Cap to Net Assets Ratio RANI|SNYR (Synergy CHC Corporation) - Market Cap to Book Value Multiple|Market Value to Book Value Ratio Rallybio Corporation (RLYB)|LEXX - Market-to-Book Ratio|Market Value to Book Value Ratio Pulmatrix, Inc. PULM|APM: Capitalization to Book Value Ratio|LYRA: Market Cap to Net Assets Ratio|Market Value to Book Value IBO (impactbiomedinc.com)|TNFA: Market Capitalization to Book Value Ratio|cbdMD - Market Value to Book Value|Market Value to Book Value Ratio PainReform Ltd.|Market-to-Book Ratio Auris Medical CYTO|Market Value to Book Value Ratio Lipella Pharmaceuticals, Inc. (LIPO)|Market Value to Book Value Ratio OPTN (OptiNose Inc)|Market Capitalization to Book Value Ratio PIRS (Pieris)|PROC: Capitalization to Book Value Ratio|Petros Pharmaceuticals - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value qlsyy.net QLI|ACELYRIN (SLRN) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio TFFP